Orakl Oncology has raised €11 million to enhance its platform that aids biopharma and biotech firms in drug development for digestive cancers. This follows a previous €3 million funding in 2023. The funds will support the creation of a commercial unit and expand their tumor avatar collection from 100 to 1,000 by 2026, focusing on pancreatic and colorectal cancers. The platform aims to reduce drug development costs and time by improving decision-making and predicting drug performance.

Aiming to become a global “startup nation” France is actively engaged in nurturing their local startup ecosystems. This ambition is supported by initiatives like La French Tech and the French Tech Visa, attracting worldwide talent and investors. Additionally, the Parisian Region catalyzes business and innovation, while Station-F stands out as the world’s largest startup campus located in France. The rise of French unicorns such as BlaBlaCar, Deezer, and Doctolib exemplifies this growth. Boasting to date, around 28 unicorns, including notable names such as Alan, Back Market, Ledger, Lydia, and Qonto. Despite the VC funds drying up all over Europe, French startups have secured €4.26 billion in funding in the first six months of 2023, surpassing the total amount raised in 2018, which stood at €3.62 billion

Paris, France, 4th October 2023 / Sciad Newswire / Orakl Oncology, a precision oncology start-up, today announces that it has raised €3 million to develop its techbio platform that integrates best-in-class biology with real-world patient data at scale to accurately model tumors and accelerate onc...